BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 17373338)

  • 1. The detection rates and tumor clinical/pathological stages of whole-body FDG-PET cancer screening.
    Ono K; Ochiai R; Yoshida T; Kitagawa M; Omagari J; Kobayashi H; Yamashita Y
    Ann Nucl Med; 2007 Jan; 21(1):65-72. PubMed ID: 17373338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of whole-body cancer screening using 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography: a preliminary report.
    Terauchi T; Murano T; Daisaki H; Kanou D; Shoda H; Kakinuma R; Hamashima C; Moriyama N; Kakizoe T
    Ann Nucl Med; 2008 Jun; 22(5):379-85. PubMed ID: 18600415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of positron emission tomography imaging to cancer screening.
    Yasuda S; Ide M; Fujii H; Nakahara T; Mochizuki Y; Takahashi W; Shohtsu A
    Br J Cancer; 2000 Dec; 83(12):1607-11. PubMed ID: 11104553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective evaluation of whole-body cancer screening with multiple modalities including [18F]fluorodeoxyglucose positron emission tomography in a healthy population: a preliminary report.
    Nishizawa S; Kojima S; Teramukai S; Inubushi M; Kodama H; Maeda Y; Okada H; Zhou B; Nagai Y; Fukushima M
    J Clin Oncol; 2009 Apr; 27(11):1767-73. PubMed ID: 19255324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer screening with FDG-PET.
    Ide M
    Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):23-7. PubMed ID: 16557201
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey.
    Minamimoto R; Senda M; Terauchi T; Jinnouchi S; Inoue T; Iinuma T; Inoue T; Ito K; Iwata H; Uno K; Oku S; Oguchi K; Tsukamoto E; Nakashima R; Nishizawa S; Fukuda H; Murano T; Yoshida T
    Ann Nucl Med; 2011 Jan; 25(1):45-54. PubMed ID: 20953985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved detection of breast cancer on FDG-PET cancer screening using breast positioning device.
    Kaida H; Ishibashi M; Fujii T; Kurata S; Ogo E; Tanaka M; Hayabuchi N
    Ann Nucl Med; 2008 Feb; 22(2):95-101. PubMed ID: 18311533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of 18F-fluorodeoxyglucose positron emission tomography with the additional help of tumor markers in cancer screening.
    Shen YY; Su CT; Chen GJ; Chen YK; Liao AC; Tsai FS
    Neoplasma; 2003; 50(3):217-21. PubMed ID: 12937856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Limited screening with versus without (18)F-fluorodeoxyglucose PET/CT for occult malignancy in unprovoked venous thromboembolism: an open-label randomised controlled trial.
    Robin P; Le Roux PY; Planquette B; Accassat S; Roy PM; Couturaud F; Ghazzar N; Prevot-Bitot N; Couturier O; Delluc A; Sanchez O; Tardy B; Le Gal G; Salaun PY;
    Lancet Oncol; 2016 Feb; 17(2):193-199. PubMed ID: 26672686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness of both PET/CT with F18-FDG and whole-body diffusion-weighted imaging in cancer screening: a preliminary report.
    Sasamori H; Uno K; Wu J
    Ann Nucl Med; 2019 Feb; 33(2):78-85. PubMed ID: 30298377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic accuracy of FDG-PET cancer screening in asymptomatic individuals: use of record linkage from the Osaka Cancer Registry.
    Sengoku T; Matsumura K; Usami M; Takahashi Y; Nakayama T
    Int J Clin Oncol; 2014 Dec; 19(6):989-97. PubMed ID: 24481919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of PET and PEt/CT imaging for cancer screening.
    Chen YK; Ding HJ; Su CT; Shen YY; Chen LK; Liao AC; Hung TZ; Hu FL; Kao CH
    Anticancer Res; 2004; 24(6):4103-8. PubMed ID: 15736459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006-2009) nationwide survey.
    Minamimoto R; Senda M; Jinnouchi S; Terauchi T; Yoshida T; Murano T; Fukuda H; Iinuma T; Uno K; Nishizawa S; Tsukamoto E; Iwata H; Inoue T; Oguchi K; Nakashima R; Inoue T
    Ann Nucl Med; 2013 Jan; 27(1):46-57. PubMed ID: 23086544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of colorectal cancer and adenomas by FDG-PET cancer screening program: results based on a nationwide Japanese survey.
    Minamimoto R; Senda M; Jinnouchi S; Terauchi T; Yoshida T; Inoue T
    Ann Nucl Med; 2014 Apr; 28(3):212-9. PubMed ID: 24347363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
    Han A; Xue J; Hu M; Zheng J; Wang X
    Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
    Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
    Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey.
    Minamimoto R; Senda M; Uno K; Jinnouchi S; Iinuma T; Ito K; Okuyama C; Oguchi K; Kawamoto M; Suzuki Y; Tsukamoto E; Terauchi T; Nakashima R; Nishio M; Nishizawa S; Fukuda H; Yoshida T; Inoue T
    Ann Nucl Med; 2007 Nov; 21(9):481-98. PubMed ID: 18030580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome.
    Masciari S; Van den Abbeele AD; Diller LR; Rastarhuyeva I; Yap J; Schneider K; Digianni L; Li FP; Fraumeni JF; Syngal S; Garber JE
    JAMA; 2008 Mar; 299(11):1315-9. PubMed ID: 18349092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.